stockportfolio.pro
BioMarin Pharmaceutical Inc. P/E Ratio 2008–2025
BioMarin Pharmaceutical Inc. (BMRN) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -3.6%/yr over 17 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 33.02 | +11.0% |
| FY 2024 | 29.74 | -73.2% |
| FY 2023 | 110.83 | -19.7% |
| FY 2022 | 137.99 | — |
| FY 2021 | — | — |
| FY 2020 | 19.49 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | 15.57 | — |
| FY 2009 | — | — |
| FY 2008 | 61.38 | — |
Source: BioMarin Pharmaceutical Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for BioMarin Pharmaceutical Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBioMarin Pharmaceutical Inc. — frequently asked questions
What is BioMarin Pharmaceutical Inc.'s price-to-earnings ratio?
BioMarin Pharmaceutical Inc. (BMRN) reported price-to-earnings ratio of 33.02 for fiscal year 2025, per its SEC filings.
How has BioMarin Pharmaceutical Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, BMRN's price-to-earnings ratio declined at roughly 3.6% per year (compound annual rate), from 61.38 to 33.02.
Where does this data come from?
Figures are computed from BioMarin Pharmaceutical Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.